ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,139.83
0.75%
Dow Jones
38,239.66
0.40%
Gold vs US Dollar
2,337.935
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,145.16
-0.93%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) News

Merck (MRK)

Merck and Co Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:MRK
DateTimeSourceHeadlineSymbolCompany
25/04/202421:40IH Market NewsU.S. Stocks Climb Well Off Worst Levels But Close Mostly LowerNYSE:MRKMerck and Co Inc
25/04/202414:09IH Market NewsFutures Pointing To Sharply Lower Open On Wall StreetNYSE:MRKMerck and Co Inc
25/04/202412:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNYSE:MRKMerck and Co Inc
25/04/202411:30Business WireMerck Announces First-Quarter 2024 Financial ResultsNYSE:MRKMerck and Co Inc
19/04/202412:04PR Newswire (Canada)Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) HNYSE:MRKMerck and Co Inc
19/04/202412:04PR Newswire (Canada)Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-contaNYSE:MRKMerck and Co Inc
10/04/202412:13IH Market NewsDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More NewsNYSE:MRKMerck and Co Inc
04/04/202411:45Business WireMerck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung CancerNYSE:MRKMerck and Co Inc
03/04/202413:00Business WireREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian CancerNYSE:MRKMerck and Co Inc
01/04/202411:45Business WireMerck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25NYSE:MRKMerck and Co Inc
28/03/202410:45Business WireEuropean Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in AdultsNYSE:MRKMerck and Co Inc
27/03/202410:54IH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNYSE:MRKMerck and Co Inc
26/03/202422:21Business WireFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)NYSE:MRKMerck and Co Inc
21/03/202410:45Business WireMerck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung CancerNYSE:MRKMerck and Co Inc
19/03/202413:00Business WireMerck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in AdultsNYSE:MRKMerck and Co Inc
15/03/202420:23PR Newswire (US)FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring PlatformNYSE:MRKMerck and Co Inc
15/03/202410:45Business WireMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical CancerNYSE:MRKMerck and Co Inc
13/03/202407:00Business WireMerck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9NYSE:MRKMerck and Co Inc
11/03/202412:15Business WireMerck Completes Acquisition of Harpoon Therapeutics, Inc.NYSE:MRKMerck and Co Inc
06/03/202415:25Business WireGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24NYSE:MRKMerck and Co Inc
05/03/202414:03IH Market NewsFutures Pointing To Continued Weakness On Wall StreetNYSE:MRKMerck and Co Inc
05/03/202411:45Business WireMerck to Participate in the Barclays 26th Annual Global Healthcare ConferenceNYSE:MRKMerck and Co Inc
04/03/202411:45Business WireMerck to Participate in the Leerink Partners Global Biopharma Conference 2024NYSE:MRKMerck and Co Inc
27/02/202411:45Business WireMerck to Participate in the TD Cowen 44th Annual Health Care ConferenceNYSE:MRKMerck and Co Inc
23/02/202411:20Business WireMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of RecurrenceNYSE:MRKMerck and Co Inc
20/02/202421:14Edgar (US Regulatory)Form 8-K - Current reportNYSE:MRKMerck and Co Inc
20/02/202411:45Business WireFDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial CarcinomaNYSE:MRKMerck and Co Inc
15/02/202421:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
15/02/202421:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
14/02/202421:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK

Your Recent History

LSE
SCLP
Scancell
LSE
ITM
Itm Power
LSE
BIRD
Blackbird
LSE
GOLD
LSE
AAZ
Anglo Asian Mining
LSE
GGP
Greatland Gold
LSE
POS
Plexus
LSE
SOLG
Solgold
LSE
LLOY
Lloyds Banking
LSE
GKP
Gulf Keystone Petroleum
LSE
AAU
Ariana Resources
LSE
AGL
Angle
LSE
SRSP
Sirius Petroleum
LSE
HUM
Hummingbird Resources
LSE
ITV
Itv
LSE
ENET
Ethernity Networks
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved